Loteprednol Etabonate
A corticosteroid eye drop with a unique retrometabolic design that metabolizes into inactive compounds in the eye, reducing the risk of elevated intraocular pressure and cataract formation compared to other steroids. It is used for ocular inflammation and allergic eye disease.
Masse moléculaire
466,9000 g/mol
LogP
3,90
TPSA
99,10 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
InChI
InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1
Molecular Formula
C24H31ClO7
HBD / HBA
1 / 7
Liaisons Rotatives
7
Atomes Lourds
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A corticosteroid eye drop with a unique retrometabolic design that metabolizes into inactive compounds in the eye, reducing the risk of elevated intraocular pressure and cataract formation compared to other steroids. It is used for ocular inflammation and allergic eye disease.
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Yes, Loteprednol Etabonate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200865. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 444025. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="loteprednol-etabonate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/loteprednol-etabonate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/loteprednol-etabonate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/loteprednol-etabonate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="loteprednol-etabonate"></drugfyi-drug>